Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its target price reduced by JPMorgan Chase & Co. from $16.00 to $15.00 in a report released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms also recently weighed in on CLBT. Weiss Ratings downgraded shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. DA Davidson restated a “buy” rating and set a $15.00 target price on shares of Cellebrite DI in a research report on Tuesday, September 15th. Lake Street Capital reduced their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Needham & Company LLC increased their price target on shares of Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $14.75.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $11.53 on Friday. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of 48.04, a price-to-earnings-growth ratio of 1.67 and a beta of 1.06. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.39. The stock’s fifty day moving average is $11.60 and its two-hundred day moving average is $13.22.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.08. Cellebrite DI had a return on equity of 17.47% and a net margin of 12.14%. The business had revenue of $149.02 million during the quarter, compared to the consensus estimate of $145.83 million. As a group, sell-side analysts forecast that Cellebrite DI will post 0.37 EPS for the current fiscal year.

Insider Activity

In other Cellebrite DI news, insider Thomas E. Hogan sold 25,299 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the sale, the insider directly owned 765,249 shares of the company’s stock, valued at $8,639,661.21. This trade represents a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Barter sold 12,134 shares of the firm’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the sale, the chief financial officer directly owned 322,085 shares in the company, valued at $3,610,572.85. This represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 57,143 shares of company stock worth $645,005. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently modified their holdings of CLBT. PNC Financial Services Group Inc. boosted its holdings in Cellebrite DI by 59.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after acquiring an additional 2,785 shares during the period. Elevation Wealth Partners LLC grew its position in Cellebrite DI by 93.3% in the third quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock valued at $66,000 after acquiring an additional 2,816 shares in the last quarter. Pacer Advisors Inc. grew its position in Cellebrite DI by 91.1% in the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after acquiring an additional 3,626 shares in the last quarter. Moody National Bank Trust Division raised its stake in shares of Cellebrite DI by 7.6% during the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after purchasing an additional 4,284 shares during the period. Finally, Quantinno Capital Management LP acquired a new position in shares of Cellebrite DI during the first quarter worth $150,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Key Cellebrite DI News

Investors following CLBT have been watching these news items:

• Positive Sentiment: Cellebrite reported Q3 revenue of $149.0 million, above the cited consensus estimate of $145.8 million, and EPS of $0.17. The company also reported 20% ARR growth, a 31% trailing-twelve-month free-cash-flow margin, and $26.7 million in net income. Cellebrite Q3 results
• Positive Sentiment: JPMorgan lowered its target from $16 to $15 but kept its Overweight rating, indicating continued optimism despite a more cautious valuation. JPMorgan analyst ratings
• Negative Sentiment: Q4 2026 revenue guidance of $145 million–$150 million fell short of the $151.6 million consensus estimate, raising a near-term concern. Full-year revenue guidance of $553 million–$558 million was broadly in line with the $556.8 million estimate.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.